These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

971 related items for PubMed ID: 18344727

  • 1. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study.
    Amsterdam JD, Shults J.
    J Clin Psychopharmacol; 2008 Apr; 28(2):171-81. PubMed ID: 18344727
    [Abstract] [Full Text] [Related]

  • 2. Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial.
    Amsterdam JD, Wang CH, Shwarz M, Shults J.
    J Affect Disord; 2009 Jan; 112(1-3):219-30. PubMed ID: 18486235
    [Abstract] [Full Text] [Related]

  • 3. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
    Amsterdam JD, Shults J.
    J Affect Disord; 2009 May; 115(1-2):234-40. PubMed ID: 18694599
    [Abstract] [Full Text] [Related]

  • 4. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression.
    Malhi GS, Ng F, Berk M.
    Aust N Z J Psychiatry; 2008 Apr; 42(4):346-9. PubMed ID: 18330778
    [Abstract] [Full Text] [Related]

  • 5. Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania.
    Sussman N, Mullen J, Paulsson B, Vågerö M.
    J Affect Disord; 2007 Apr; 100 Suppl 1():S55-63. PubMed ID: 17383736
    [Abstract] [Full Text] [Related]

  • 6. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).
    Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M, EMBOLDEN I (Trial 001) Investigators.
    J Clin Psychiatry; 2010 Feb; 71(2):150-62. PubMed ID: 20122369
    [Abstract] [Full Text] [Related]

  • 7. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms.
    McIntyre RS, Konarski JZ, Jones M, Paulsson B.
    J Affect Disord; 2007 Feb; 100 Suppl 1():S5-14. PubMed ID: 17391773
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial.
    Bowden CL, Mosolov S, Hranov L, Chen E, Habil H, Kongsakon R, Manfredi R, Lin HN.
    Int Clin Psychopharmacol; 2010 Mar; 25(2):60-7. PubMed ID: 20101186
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
    Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR, BOLDER II Study Group.
    J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817
    [Abstract] [Full Text] [Related]

  • 10. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 11. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression.
    Ladd CO, Newport DJ, Ragan KA, Loughhead A, Stowe ZN.
    Depress Anxiety; 2005 Jan; 22(2):94-7. PubMed ID: 16094663
    [Abstract] [Full Text] [Related]

  • 12. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
    Simon JS, Aguiar LM, Kunz NR, Lei D.
    J Psychiatr Res; 2004 Jan; 38(3):249-57. PubMed ID: 15003430
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of high dose of venlafaxine XL in treatment resistant major depression.
    Mbaya P.
    Hum Psychopharmacol; 2002 Oct; 17(7):335-9. PubMed ID: 12415551
    [Abstract] [Full Text] [Related]

  • 14. Venlafaxine for treatment-resistant unipolar depression.
    Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J.
    J Clin Psychopharmacol; 1994 Dec; 14(6):419-23. PubMed ID: 7884023
    [Abstract] [Full Text] [Related]

  • 15. Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine.
    Buckley PF, Paulsson B, Brecher M.
    J Affect Disord; 2007 Dec; 100 Suppl 1():S33-43. PubMed ID: 17376537
    [Abstract] [Full Text] [Related]

  • 16. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary MO, Modell J.
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [Abstract] [Full Text] [Related]

  • 17. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder.
    DelBello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M, Bryan H, Vogel D, Sampang S, Delgado SV, Sorter M, Strakowski SM.
    Bipolar Disord; 2009 Aug; 11(5):483-93. PubMed ID: 19624387
    [Abstract] [Full Text] [Related]

  • 18. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients.
    Schweizer E, Feighner J, Mandos LA, Rickels K.
    J Clin Psychiatry; 1994 Mar; 55(3):104-8. PubMed ID: 8071246
    [Abstract] [Full Text] [Related]

  • 19. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study.
    Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, Sweitzer DE.
    Bipolar Disord; 2004 Jun; 6(3):213-23. PubMed ID: 15117400
    [Abstract] [Full Text] [Related]

  • 20. Low dosage lithium augmentation in venlafaxine resistant depression: an open-label study.
    Alevizos B, Alevizos E, Leonardou A, Zervas I.
    Psychiatriki; 2012 Jun; 23(2):143-8. PubMed ID: 22796912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.